Greenwich LifeSciences, Inc. SEC filings GLSI
Greenwich LifeSciences, Inc. has 279 filings in SEC EDGAR's recent list, going back to Jan 27, 2020. Its latest annual report, Form ARS, was filed on Oct 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Dec 18, 2025 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-K | Filing | Mar 31, 2026 | Dec 31, 2025 |
| NT 10-Q | Filing | May 15, 2025 | Mar 31, 2025 |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Oct 17, 2024 | — |
| CORRESP | Letter to the SEC | Oct 15, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2024 | — |
| D | Filing | Jun 18, 2024 | — |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| NT 10-Q | Filing | Aug 14, 2023 | Jun 30, 2023 |
| NT 10-Q | Filing | May 15, 2023 | Mar 31, 2023 |
| NT 10-Q | Filing | May 17, 2022 | Mar 31, 2022 |
| EFFECT | Filing | Apr 6, 2022 | — |
| CORRESP | Letter to the SEC | Apr 4, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2022 | — |
| NT 10-Q | Filing | May 17, 2021 | Mar 31, 2021 |
| EFFECT | Filing | Dec 17, 2020 | — |
| CORRESP | Letter to the SEC | Dec 15, 2020 | — |
| CORRESP | Letter to the SEC | Dec 15, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2020 | — |
| DRS | Filing | Dec 7, 2020 | — |
| EFFECT | Filing | Sep 24, 2020 | — |
| CERT | Filing | Sep 24, 2020 | — |
| 8-A12B | For registration of certain classes | Sep 23, 2020 | — |
| CORRESP | Letter to the SEC | Sep 22, 2020 | — |
| CORRESP | Letter to the SEC | Sep 22, 2020 | — |
| CORRESP | Letter to the SEC | Jun 26, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2020 | — |
| CORRESP | Letter to the SEC | Jun 22, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2020 | — |
| CORRESP | Letter to the SEC | May 29, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2020 | — |
| DRSLTR | Filing | Apr 7, 2020 | — |
| DRS/A | Filing | Apr 7, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 20, 2020 | — |
| DRS | Filing | Jan 28, 2020 | — |
| DRSLTR | Filing | Jan 27, 2020 | — |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GLSI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Stafford, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1799788
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.